How to buy Puma Biotechnology stock (PBYI)

Puma Biotechnology is a biotechnology business based in the US. Puma Biotechnology shares (PBYI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.75 – a decrease of 4.51% over the previous week. Puma Biotechnology employs 185 staff and has a trailing 12-month revenue of around $243.6 million.

Our top picks for where to buy Puma Biotechnology stock

Buy Puma Biotechnology stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Puma Biotechnology stock price (NASDAQ: PBYI)

Use our graph to track the performance of PBYI stocks over time.

Puma Biotechnology shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$2.75
52-week range	$2.23 - $7.73
50-day moving average more info button	$2.94
200-day moving average more info button	$3.62
Wall St. target price	$4.33
PE ratio more info button	5.8936
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.47

Is it a good time to buy Puma Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Puma Biotechnology price performance over time

Historical closes compared with the close of $2.75 from 2024-12-20

1 week (2024-12-13)	-4.51%
1 month (2024-11-22)	-8.33%
3 months (2024-09-20)	5.77%
6 months (2024-06-21)	-8.03%

1 year (2023-12-21)	-30.20%
2 years (2022-12-21)	-44.89%
3 years (2021-12-21)	3.38
5 years (2019-12-20)	8.26

Is Puma Biotechnology stock undervalued or overvalued?

Valuing Puma Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Puma Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Puma Biotechnology's P/E ratio

Puma Biotechnology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Puma Biotechnology shares trade at around 6x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Puma Biotechnology's PEG ratio

Puma Biotechnology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.03. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Puma Biotechnology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Puma Biotechnology's EBITDA

Puma Biotechnology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $44.6 million.

The EBITDA is a measure of a Puma Biotechnology's overall financial performance and is widely used to measure a its profitability.

Puma Biotechnology financials

Revenue TTM	$243.6 million
Operating margin TTM	27.41%
Gross profit TTM	$172.9 million
Return on assets TTM	9.73%
Return on equity TTM	42.32%
Profit margin	9.54%
Book value	$1.45
Market Capitalization more info button	$136 million

TTM: trailing 12 months

Puma Biotechnology share dividends

We're not expecting Puma Biotechnology to pay a dividend over the next 12 months.

Puma Biotechnology share price volatility

Over the last 12 months, Puma Biotechnology's shares have ranged in value from as little as $2.225 up to $7.73. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Puma Biotechnology's is 1.08. This would suggest that Puma Biotechnology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Puma Biotechnology overview

Puma Biotechnology, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd.

Frequently asked questions

What percentage of Puma Biotechnology is owned by insiders or institutions?
Currently 15.141% of Puma Biotechnology shares are held by insiders and 67.751% by institutions. How many people work for Puma Biotechnology?
Latest data suggests 185 work at Puma Biotechnology. When does the fiscal year end for Puma Biotechnology?
Puma Biotechnology's fiscal year ends in December. Where is Puma Biotechnology based?
Puma Biotechnology's address is: 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024 What is Puma Biotechnology's ISIN number?
Puma Biotechnology's international securities identification number is: US74587V1070 What is Puma Biotechnology's CUSIP number?
Puma Biotechnology's Committee on Uniform Securities Identification Procedures number is: 74587V107